VIVUS
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, VIVUS sits in the top decile of US sponsors by registered trial count (#473 of 15,742 sponsors by registered trial count).
VIVUS: 35 sponsored US clinical trials, 1 recruiting.
VIVUS sponsors 35 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 32 completed. 14 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 2 trials.
Top-decile sponsor footprint
VIVUS ranks in the top decile of sponsors by registered trial count (#473 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
32 of 34 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
35 total, page 1 of 1
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
NCT06915246
A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects
NCT05215418
A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity
NCT03922945
A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents
NCT02714062
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
NCT02229214
Safety Study Looking at the Effects of Stendra on Vision
NCT02033200
Study Evaluating the Effects of Avanafil on Semen Parameters
NCT01768676
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
NCT01698684
VI-1121 for the Treatment Alzheimer's Disease
NCT01428362
Drug Interaction Study of Avanafil and Enalapril or Amlodipine
NCT01117038
Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin
NCT01100021
A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®
NCT01096329
A Pharmacokinetic Study of Avanfil in Healthy Young Male Subjects
NCT00914511
Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy
NCT00895011
Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction
NCT00853606
A Study to Evaluate How VI-0521 Affect Cardiac Repolarization in Healthy Male and Female Volunteers
NCT00839891
A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.
NCT00842400
Evaluate the Effect of VI-0521 on the Pharmacokinetics of Oral Contraceptive in Healthy Female Subjects
NCT00821496
A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.
NCT00806260
Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)
NCT00809471
Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED
NCT00790751
A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment
NCT00768404
To Evaluate The Effect Of Ketoconazole, Ritonavir and Erythromycin on the Safety and Pharmacokinetics of Avanafil
NCT00770042
A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment
NCT00768209
A Thorough EKG Safety Study of TA-1790 (Avanafil)
NCT00769041
A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults
NCT00745251
Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults
NCT00737633
A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults
NCT00600067
A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults
NCT00563368
Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults
NCT00554216
Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions
NCT00553787
Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults
NCT00518466
Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics
NCT00486291
Topical Alprostadil for Female Sexual Arousal Disorder
NCT00324948
Study to Evaluate Hemodynamic Response to to a Sublingual Dose of Glyceryl Trinitrate in Subjects Receiving TA-1790, Sildenafil Citrate, and Placebo
NCT01616485
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 7 |
| Phase 3 | 7 |
| Phase 4 | 7 |
Therapeutic Areas
What is open in the VIVUS pipeline
1 recruiting of 35 indexed (3% open); 32 completed (91%).
Phase mix: 14 late (III/IV) vs 21 early (I/II) (balanced across stages).
Top condition: Obesity (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
VIVUS: open-pipeline peers nationwide
Peers matched on 35 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
VIVUS sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 35 trials (± recruiting share)
- ACADIA Pharmaceuticals · 35 trials · 9% recruiting
- INSYS Therapeutics · 35 trials · 0% recruiting
- Merz North America · 35 trials · 3% recruiting
- Palo Alto Veterans Institute for Research · 35 trials · 20% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Eastern Cooperative Oncology Group · 3% recruiting · 141 trials
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · 3% recruiting · 138 trials
- Enanta Pharmaceuticals · 3% recruiting · 36 trials
- Idorsia Pharmaceuticals · 3% recruiting · 34 trials
Related
What to do with this VIVUS page
35 registered trials is a research-attention snapshot, not an endorsement of VIVUS or any single study.
- 1 of VIVUS's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition VIVUS studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
VIVUS pipeline card: 35 registered trials from official public datasets.Report a data error.